NVS
January 31, 2024 - AI Summary
Overvalued by 3.7% based on the discounted cash flow analysis.
Market cap | $219.45 Billion |
---|---|
Enterprise Value | $237.04 Billion |
Dividend Yield | $3.7395 (3.73%) |
Earnings per Share | $7.34 |
Beta | 0.37 |
Outstanding Shares | 2,189,930,497 |
Avg 30 Day Volume | 1,756,023 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 14.4 |
---|---|
PEG | 83.56 |
Price to Sales | 5.11 |
Price to Book Ratio | 5.67 |
Enterprise Value to Revenue | 5.2 |
Enterprise Value to EBIT | 22.38 |
Enterprise Value to Net Income | 15 |
Total Debt to Enterprise | 0.12 |
Debt to Equity | 0.69 |
No data
No data
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...